In addition, the median follow-up period was relatively short (42 months and 45 months in the PSM cohort), considering that disease-related events occur steadily 5 years after diagnosis in HR+/HER2- breast cancer [28]. The gene discussed is ERBB2; the disease is breast carcinoma.